Type 1 Diabetes Mellitus Effect on Bone Mineral Density
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Because the diabetics are fracturing at a younger age than the general population (12), this leads us to believe there are significant factors that lead to fracture in Type 1 diabetes mellitus (DM) other than bone mineral density (BMD). Very little longitudinal data exists on BMD in adults with Type 1 DM and the effects of glucose control on BMD. No longitudinal data exists on pQCT in adults with Type 1 DM.
Hypothesis: Adult subjects with diabetes and poor glucose control will lose bone mineral density (BMD) as measured by DXA compared to age and sex matched healthy controls.
| Condition |
|---|
|
Diabetes Mellitus Osteoporosis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Type 1 DM Effect on BMD: a Longitudinal Study in Adults |
- Bone mineral Density [ Time Frame: 5 years ] [ Designated as safety issue: No ]Bone mineral density will be measured yearly for 5 years
Biospecimen Retention: Samples Without DNA
We will be storing serum samples. No genetic tests will be performed on these.
| Estimated Enrollment: | 200 |
| Study Start Date: | August 2012 |
| Estimated Study Completion Date: | July 2017 |
| Estimated Primary Completion Date: | July 2017 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Diabetes
patients with Type 1 Diabetes Mellitus
|
|
Control
Age and sex matched control subjects
|
Detailed Description:
Because the diabetics are fracturing at a younger age than the general population(12), this leads us to believe there are significant factors that lead to fracture in Type 1 DM other than BMD. Very little longitudinal data exists on BMD in adults with Type 1 DM and the effects of glucose control on BMD. No longitudinal data exists on pQCT in adults with Type 1 DM.
Hypothesis: Adult subjects with diabetes and poor glucose control will lose bone mineral density (BMD) as measured by DXA compared to age and sex matched healthy controls.
Eligibility| Ages Eligible for Study: | 19 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Subjects who have Type 1 DM and their age and sex matched control and have been enrolled in a study of Type 1 DM and bone and had a baseline DXA and pQCT during the last 4 years. Persons that completed visit 1 for the previous study and had a DXA and pQCT done will be invited back for repeat DXA and pQCT measurement. If a diabetic patient does not have an age and sex matched control or their control does not want to be in the longitudinal study a new age and sex matched control will be recruited.
Inclusion Criteria:
- diabetic patients must have completed Visit 1 of the previous study.
Contacts and Locations| Contact: Julie Stubby, RN | 402-280-4958 | jas@creighton.edu |
| Contact: Laura AG Armas | 402-280-4470 | larmas@creighton.edu |
| United States, Nebraska | |
| Creighton University | Not yet recruiting |
| Omaha, Nebraska, United States, 68131 | |
| Contact: Julie Stubby, RN 402-280-4958 jas@creighton.edu | |
| Contact: Laura Armas 402-280-4470 larmas@creighton.edu | |
| Principal Investigator: | Laura Armas, MD,MS | Creighton University |
More Information
No publications provided
| Responsible Party: | Creighton University |
| ClinicalTrials.gov Identifier: | NCT01633684 History of Changes |
| Other Study ID Numbers: | Creighton 14 |
| Study First Received: | July 2, 2012 |
| Last Updated: | July 3, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Creighton University:
|
diabetes mellitus bone |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 1 Osteoporosis Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Autoimmune Diseases Immune System Diseases Bone Diseases, Metabolic Bone Diseases Musculoskeletal Diseases |
ClinicalTrials.gov processed this record on May 22, 2013